Dr Prasad on Next Steps for the ENVISION Trial in NMIBC | OncLive Sandip M. Prasad, MD, discusses future directions for investigating mitomycin intravesical solution in the ENVISION trial for NMIBC.

WATCH: Sandip M. Prasad, MD, discusses future directions for investigating mitomycin intravesical solution in the ENVISION trial for NMIBC. #GU26 #oncology #nmibc
www.onclive.com/view/dr-pras...

Dr Prasad on the ENVISION Trial in NMIBC | OncLive Sandip M. Prasad, MD, discusses prior data from the phase 3 ENVISION trial in NMIBC.

WATCH: Sandip M. Prasad, MD, of Atlantic Health discusses prior data from the phase 3 ENVISION trial in NMIBC. #GU26 #oncology #nmibc
www.onclive.com/view/dr-pras...

Neoadjuvant Mitomycin C Before TURBT May Cut NMIBC Recurrence, Progression Risks - Oncology Nurse Advisor A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

In #NMIBC, immediate administration of 2 doses of neoadjuvant intravesical mitomycin C chemotherapy prior to TURBT may reduce recurrence and progression risks compared with TURBT alone. From @renalurologynews.bsky.social.

https://bit.ly/41gINY2

#blcsm #bladdercancer

Nadofaragene Firadenovec Is Added to NCCN Guidelines in BCG-Unresponsive Papillary NMIBC Without CIS | OncLive Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

The NCCN guidelines have now added nadofaragene firadenovec-vncg (Adstiladrin) as a category 2A recommendation for patients with BCG-unresponsive NMIBC with papillary Ta/T1 tumors without concomitant carcinoma in situ. #BladderCancer #NMIBC #oncology
🔗 Read more: www.onclive.com/view/nadofar...

Now on demand: Expert insights on managing BCG-unresponsive #NMIBC and new bladder-sparing treatments.
Explore clinical strategies to help improve outcomes and preserve quality of life.

Watch now ➡️ bit.ly/4shPKUS

#Urology #BladderCancer #CME #NMIBC #MedicalEducation

Management of high-risk NMIBC is evolving beyond BCG alone.

Get practical insights on immunotherapy plus BCG, including key clinical evidence and strategies for managing patients in everyday practice.

👉 Access the program: bit.ly/3MT4yKg

#NMIBC #BladderCancer #Urology

For clinicians treating NMIBC, tolerability drives success with intravesical therapy.

Get practical tips to prevent early AEs, manage challenges, and improve procedural technique.

👉 Access the program: bit.ly/46CiLlk

#HCPEducation #NMIBC #BladderCancer #Urology #Oncology

Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study. To elicit preferences for bladder-sparing treatments among patients with non-muscle-invasive bladder cancer (NMIBC) in the United States.Patients with self-reported NMIBC completed an online discrete-...

New research explores how patients with non-muscle-invasive bladder cancer weigh bladder-sparing treatment choices as options expand. Patient preference matters in this new treatment era.
#BladderCancer #NMIBC #PatientChoice #Oncology #TCSC
www.urotoday.com/recent-abstr...

Synapse: Your Connection to our MSK Authors
Meet: Alvin Chun chin Goh
Research Focus: Surgery; Associate Attending

Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Guérin (BCG)
synapse.mskcc.org/synapse/work...

#BladderCancer #NMIBC
#NonMuscleInvasiveBladderCancer

ASCO Publications

Variables priorizadas por los pacientes son similares o mejores en los pacientes con cáncer de vejiga recurrente de alto grado sin invasión a músculo que escogen la cistectomía radical comparada con la terapia de preservación de vejiga #NMIBC #Cystectomy ascopubs.org/doi/full/10....

How can we mitigate potential risks in #NMIBC treatment? Morgan Rouprêt shares his thoughts at #ESMO2025, including incorporating pathological assessment into treatment selection. For more congress highlights and the latest trial data, head to Medthority now #MedSky #OncSky

ow.ly/EyRT50Y5WZ4

As the treatment landscape for #NMIBC continues to evolve, get the insights you need to know with Medthority. Log in to hear from Joshua Meeks, Félix Guerrero-Ramos, and @ashishkamatmd.bsky.social, plus catch up with highlights from #ESMO25, #ASCO25, and more! #MedSky #OncSky

ow.ly/mFcc50XZKzO

#BCG may be less effective in patients who develop metachronous #NMIBC after radical nephrouretectomy for #UTUC. Reported at #SUO25 by Yu Guang Tan, MBBS, of Singapore General Hospital covered by @renalurologynews.bsky.social.
https://bit.ly/4sJXtf5

#bladdercancer #blcsm

Cretostimogene Yields Durable Event-Free Survival in Papillary, BCG-Unresponsive NMIBC - Oncology Nurse Advisor The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.

Cretostimogene grenadenorepvec prolongs high-grade event-free survival in patients with high-risk, papillary-only #NMIBC that fails to respond to BCG. Mark Tyson, MD of @mayoclinic.org presented at #SUO25, from @renalurologynews.bsky.social.

https://bit.ly/4paeufm

#bladdercancer

GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

#GSK #depemokimab #severeasthma #Exdensur #CRSwNP #respiratory #immunology #inflammation #Nucala #mepolizumab #COPD #rarediseases #SerumLifeScienceEurope #Anktiva #NMIBC #SFLPharma #Aumseqa #NSCLC #Cytokinetics #Myqorzo #hypertrophiccardiomyopathy #Moderna #Mnexspike #COVID19vaccine
zurl.co/l8WfN

Cystectomy or bladder-sparing therapy? Support your patients to tackle the toughest decision in #NMIBC management with expert and patient insights in this episode of Expert voices - Navigating NMIBC, hosted by @ashishkamatmd.bsky.social #MedSky #MedicalPodcast #OncSky

ow.ly/Wkpc50XImRn

Exciting news: our non-viral gene therapy for #NMIBC, has been accepted into the FDA’s CDRP Program. The Program is designed to strengthen our engagement with the FDA on CMC requirements and supports our preparations for a future planned BLA submission. engene.com/engenes-deta...

My bladder cancer is a sneaky little bugger. I keep finding it hiding under the bed gobbling sweets I said were off limits. It is constantly playing hide and seek at the most inconvenient times so I must drop everything to find it. #NMIBC #fuckcancer #bladdercancer #women'scancer

My bladder cancer is like a toddler. I repeatedly have to risk my own safety to stop it from running out into traffic. It refuses to go down for it's nap - FORGET about bedtime. #NMIBC #bladdercancer #womenscancer #fuckcancer

What are the #NMIBC updates from #ESMO25 you need to know? @ashishkamatmd.bsky.social and Paolo Gontero unpack the latest insights from last month's event, including the impact of BCG therapy shortages and how AI-driven pathology is reshaping risk stratification #MedSky #OncSky

ow.ly/LPaL50Xy4ZJ

Recurrent Non-Muscle Invasive Bladder Cancer Often Matches Primary Disease Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show direct progression to muscle-invasive or metastatic dise...

Recurrent non-muscle invasive #bladdercancer typically follows the same clinical and pathologic characteristics as the primary #tumor, even on second or third recurrences. Published in @elsevierconnect.bsky.social journal Clinical Genitourinary Cancer.

https://bit.ly/4oGEEH2

#NMIBC #gucsm

SunRISe-1 Study: TAR-200 vs PD-1 Immunotherapy in BCG-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer - OncoDaily SunRISe-1 shows TAR-200 achieves superior complete responses vs PD-1 immunotherapy in BCG-unresponsive high-risk NMIBC, offering a promising bladder-sparing option.

SunRISe-1 Study: TAR-200 vs PD-1 Immunotherapy in BCG-Unresponsive High-Risk Non–Non-Muscle-Invasive Bladder Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BladderCancer #NMIBC

How can you help patients and caregivers navigate the impacts of an #NMIBC diagnosis? Host @ashishkamatmd.bsky.social talks to husband and wife Doug and Camille in the latest episode of Expert voices - Navigating NMIBC. Listen now for first-hand patient insights #MedSky #MedEd

ow.ly/3JlR50Xu1b6

Detalimogene Produces 63% CR Rate in BCG-Unresponsive NMIBC with CIS | OncLive Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

Detalimogene Produces 63% CR Rate in BCG-Unresponsive #NMIBC with CIS #oncology

www.onclive.com/view/detalim...

Enhance #NMIBC care with expert guidance on gemcitabine intravesical therapy-evidence, workflows, AE management, and patient engagement.

🎥 Watch now: bit.ly/42ZozUc

What does Félix Guerrero-Ramos think of upcoming shifts in clinical practice when managing #NMIBC? Guerrero-Ramos discusses what he’d like to see in future guidelines, including biomarker selection and better patient classification, at #ESMO25 #MedSky #OncSky

ow.ly/pX2E50XooEi

UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC | OncLive UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.

UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC #oncology #NMIBC #urothelialcancer
www.onclive.com/view/ugn-103...

$155 Bladder Cancer Research Opportunity from Pillar Patient Advocates! If interested, please compete the registration at www.research.net/r/99MXN32 or email Cobermaier@pillaradvocates.com
#bladdercancer #bladdercancerwarrior #NMIBC #cancerresearch #sponsored

Missed out on #ESMO25? Stay tuned for upcoming congress highlights that fit around your busy schedule. For now, catch up with the latest insights on improving the patient experience in #bladdercancer care from Joshua Meeks and Félix Guerrero-Ramos #MedSky #OncSky #NMIBC

ow.ly/e2oz50Xgh8b

📰 It’s news-day Tuesday! Catch up with the updates you need to know from #ESMO25 with articles by our expert scientific team. From #NSCLC to #NMIBC, scroll through our news page for the latest trial data and insights on a potential “new standard of care” #MedSky #OncSky

ow.ly/ssrv50XfpYg